Physician profile
Emily Edwards
NPI 1235582313
$5,787.20
in general payments reported to CMS, 2019-2025
18 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $394 · 2021: $629 · 2022: $1,197 · 2023: $1,121 · 2024: $823 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,690.05 | 2022-2025 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $1,247.68 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,099.20 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $356.16 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $295.49 | 2023-2025 | Tearcare System, Omni Surgical System |
| Allergan, INC. | $168.15 | 2019-2022 | |
| Lkc Technologies, INC. | $137.56 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $121.70 | 2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $106.69 | 2022-2023 | Contact Lens, Spectacle Lenses |
| Abbvie INC. | $92.16 | 2024 | |
| Rxsight INC | $82.59 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Optovue, INC. | $80.84 | 2019 | |
| Alcon Vision LLC | $77.52 | 2023 | Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $71.23 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $57.56 | 2023 | Tecnis Simplicity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $57.17 | 2019-2020 | |
| Shire North American Group INC | $31.01 | 2019 | |
| Oyster Point Pharma, INC. | $14.44 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.